Literature DB >> 11313992

The RFG oligomerization domain mediates kinase activation and re-localization of the RET/PTC3 oncoprotein to the plasma membrane.

C Monaco1, R Visconti, M V Barone, G M Pierantoni, M T Berlingieri, C De Lorenzo, A Mineo, G Vecchio, A Fusco, M Santoro.   

Abstract

The RET/PTC3 oncogene arises from the fusion between the N-terminal encoding domain of the RFG gene and the tyrosine kinase encoding domain of RET receptor. RET/PTC3 is very frequent in papillary thyroid carcinomas, especially in children exposed to the Chernobyl accident. We have studied the functional consequences of the RFG-RET fusion. Here we show that the N-terminal coiled-coil domain of RGF mediates oligomerization and activation of the kinase and of the transforming capability of RET/PTC3. In addition, the RFG coiled-coil domain mediates a physical association between RET/PTC3 and RGF proteins, rendering RFG a bona fide substrate of RET/PTC3 kinase. Finally, we show that the coiled-coil domain of RGF is essential for the distribution of the RET/PTC3 protein at the membrane/particulate cell compartment level, where also most of the RFG protein is localized. We propose that fusion to the RFG coiled-coil domain provides RET kinase with a scaffold that mediates oligomerization and re-localization of the RET/PTC3 protein, a process that may be crucial for the signalling of this specific RET/PTC variant.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313992     DOI: 10.1038/sj.onc.1204127

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  20 in total

Review 1.  Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.

Authors:  Alexander Drilon; Zishuo I Hu; Gillianne G Y Lai; Daniel S W Tan
Journal:  Nat Rev Clin Oncol       Date:  2017-11-14       Impact factor: 66.675

2.  Autophagy-Independent Lysosomal Targeting Regulated by ULK1/2-FIP200 and ATG9.

Authors:  Jonathan M Goodwin; William E Dowdle; Rowena DeJesus; Zuncai Wang; Philip Bergman; Marek Kobylarz; Alicia Lindeman; Ramnik J Xavier; Gregory McAllister; Beat Nyfeler; Gregory Hoffman; Leon O Murphy
Journal:  Cell Rep       Date:  2017-09-05       Impact factor: 9.423

3.  Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma.

Authors:  Fulvio Basolo; Riccardo Giannini; Carmen Monaco; Rosa Marina Melillo; Francesca Carlomagno; Martina Pancrazi; Giuliana Salvatore; Gennaro Chiappetta; Furio Pacini; Rossella Elisei; Paolo Miccoli; Aldo Pinchera; Alfredo Fusco; Massimo Santoro
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

Review 4.  Thyroid Cancer: Role of RET and Beyond.

Authors:  Francesca Carlomagno
Journal:  Eur Thyroid J       Date:  2012-03-28

5.  Overexpression of leucocyte common antigen (LAR) P-subunit in thyroid carcinomas.

Authors:  N Konishi; K Tsujikawa; H Yamamoto; E Ishida; M Nakamura; K Shimada; K Yane; H Yamashita; S Noguchi
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

Review 6.  Central role of RET in thyroid cancer.

Authors:  Massimo Santoro; Francesca Carlomagno
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-12-01       Impact factor: 10.005

Review 7.  RET/PTC rearrangement in thyroid tumors.

Authors:  Yuri E Nikiforov
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

Review 8.  Tyrosine kinase gene rearrangements in epithelial malignancies.

Authors:  Alice T Shaw; Peggy P Hsu; Mark M Awad; Jeffrey A Engelman
Journal:  Nat Rev Cancer       Date:  2013-10-17       Impact factor: 60.716

9.  Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer.

Authors:  V Vasko; M Saji; E Hardy; M Kruhlak; A Larin; V Savchenko; M Miyakawa; O Isozaki; H Murakami; T Tsushima; K D Burman; C De Micco; M D Ringel
Journal:  J Med Genet       Date:  2004-03       Impact factor: 6.318

10.  The RET/PTC3 oncogene activates classical NF-κB by stabilizing NIK.

Authors:  R J Neely; M S Brose; C M Gray; K A McCorkell; J M Leibowitz; C Ma; J L Rothstein; M J May
Journal:  Oncogene       Date:  2010-09-06       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.